Mirum Pharmaceuticals' Ctexli wins FDA approval for CTX, a rare lipid storage disease. The company projects 2025 global sales of $420–$435 million.

Today, the U.S. Food and Drug Administration approved Ctexli (chenodiol) for the treatment of cerebrotendinous xanthomatosis (CTX) in adults. Ctexli is the first FDA-approved drug to treat CTX, a very ...

Preeclampsia, a complication of pregnancy characterized by high blood pressure and high levels of protein in the urine ...

Johns Hopkins University School of Medicine researchers have discovered a dual regulatory mechanism safeguarding ...

"It highlights the importance these methods hold." Researchers reveal groundbreaking method to predict how childhood health ...

The following is a summary of “Causal inference study of plasma proteins and blood metabolites mediating the effect of ...

Alzheimer’s Disease (AD) is a major neurodegenerative disorder contributing to 60-70% of dementia cases globally, affecting approximately 50 million ...

Researchers have discovered that naturally occurring gut microbes produce indoles—compounds that play a key role in ...

The bill bars measured marijuana metabolites in a person’s urine, blood serum, or plasma from determining a per se charge in ...

A six-second cycling test has been shown to reliably and efficiently measure peak power in endurance athletes, offering an ...

An international team led by researchers at the University of Toronto has found a compound in ginger, called furanodienone ...